Andrew has over 30 years’ experience in finance and management. He is consultant CFO at PhoreMost and CFO of Artios Pharma. He was co-founder and CFO of Acacia Pharma, and CEO of Amura Therapeutics. Andrew has been the CFO of several biotech companies, including Bicycle Therapeutics, Kymab, Mission Therapeutics and Virttu Biologics.
Andrew has raised significant amounts of funding, including over $500 million in healthcare private equity and has completed many acquisitions, disposals and restructuring deals in the healthcare market. He has over 15 years’ corporate finance and capital markets experience from PricewaterhouseCoopers and UBS.